The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease

被引:31
|
作者
Almeda-Valdes, Paloma [1 ]
Olivos, Nancy E. Aguilar [2 ]
Barranco-Fragoso, Beatriz [3 ]
Uribe, Misael [2 ]
Mendez-Sanchez, Nahum [2 ]
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Endocrinol & Metab Dept, Mexico City 14080, DF, Mexico
[2] Med Sur Clin & Fdn, Liver Res Unit, Mexico City 14050, DF, Mexico
[3] Natl Med Ctr 20 Noviembre, Dept Gastroenterol, Mexico City 03229, DF, Mexico
关键词
CLASS-II COMPLEXES; KILLER T-CELLS; LANGERHANS CELLS; PREVALENCE; IMMUNITY; MATURE; LIPOPOLYSACCHARIDE; ACCUMULATION; MATURATION; CHEMOKINES;
D O I
10.1155/2015/768071
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease. NAFLD encompasses a wide range of pathologies, from simple steatosis to steatosis with inflammation to fibrosis. The pathogenesis of NAFLD progression has not been completely elucidated, and different liver cells could be implicated. This review focuses on the current evidence of the role of liver dendritic cells (DCs) in the progression from NAFLD to fibrosis. Liver DCs are a heterogeneous population of hepatic antigen-presenting cells; their main function is to induce T-cell mediated immunity by antigen processing and presentation to T cells. During the steady state liver DCs are immature and tolerogenic. However, in an environment of chronic inflammation, DCs are transformed to potent inducers of immune responses. There is evidence about the role of DC in liver fibrosis, but it is not clearly understood. Interestingly, there might be a link between lipid metabolism and DC function, suggesting that immunogenic DCs are associated with liver lipid storage, representing a possible pathophysiological mechanism in NAFLD development. A better understanding of the interaction between inflammatory pathways and the different cell types and the effect on the progression of NAFLD is of great relevance.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease
    Nati, Marina
    Chung, Kyoung-Jin
    Chavakis, Triantafyllos
    JOURNAL OF INNATE IMMUNITY, 2022, 14 (01) : 31 - 41
  • [22] A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts
    Knochel, Jane
    Bergenholm, Linnea
    Ibrahim, Eman
    Kechagias, Stergios
    Hansson, Sara
    Liljeblad, Mathias
    Nasr, Patrik
    Carlsson, Bjorn
    Ekstedt, Mattias
    Ueckert, Sebastian
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (12): : 2038 - 2049
  • [23] LONG-ACTING INSULIN IS ASSOCIATED WITH PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Seo, Dong Joo
    Lee, David
    Rai, Puja
    Zelman, Sara
    Fan, Gregory Hongyuan
    Malik, Raza
    HEPATOLOGY, 2020, 72 : 1053 - 1053
  • [24] Progression of Liver Fibrosis Is Associated with Non-Liver-Related Mortality in Patients with Nonalcoholic Fatty Liver Disease
    Miyake, Nozomi
    Tada, Toshifumi
    Kobayashi, Natsuko
    Toyoda, Hidenori
    Kumada, Takashi
    HEPATOLOGY, 2018, 68 : 974A - 974A
  • [25] Progression of Liver Fibrosis Is Associated With Non-Liver-Related Mortality in Patients With Nonalcoholic Fatty Liver Disease
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Mizuno, Kazuyuki
    Sone, Yasuhiro
    Akita, Tomoyuki
    Tanaka, Junko
    HEPATOLOGY COMMUNICATIONS, 2017, 1 (09) : 899 - 910
  • [26] Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease
    Nair, Bhagyalakshmi
    Nath, Lekshmi R.
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2020, 40 (03) : 195 - 200
  • [27] New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease
    Zuo, Guangmin
    Xuan, Liping
    Xin, Zhuojun
    Xu, Yu
    Lu, Jieli
    Chen, Yuhong
    Dai, Meng
    Zhang, Di
    Wang, Weiqing
    Li, Mian
    Bi, Yufang
    Ning, Guang
    Xu, Min
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (10): : E3957 - E3968
  • [28] Evaluation of fibrosis in patients with nonalcoholic fatty liver disease
    Montano-Loza, Aldo J.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2022, 87 (01): : 1 - 3
  • [29] OSTEOPONTIN PROMOTES NONALCOHOLIC FATTY LIVER DISEASE PROGRESSION
    Syn, Wing-Kin
    Choi, Steve S.
    Liaskou, Evaggelia
    Karaca, Gamze F.
    Oo, Ye H.
    Pereira, Thiago A.
    Bhattacharya, Syamal D.
    Moylan, Cynthia A.
    Agboola, Kolade M.
    Omenetti, Alessia
    Schroder, Vanessa T.
    Mi, ZhiYong
    Guy, Cynthia D.
    Abdelmalek, Monal F.
    Potti, Anil
    Kuo, Paul C.
    Michelotti, Gregory A.
    Adams, David H.
    Diehl, Anna Mae
    HEPATOLOGY, 2010, 52 (04) : 350A - 351A
  • [30] Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
    Dixon, JB
    Bhathal, PS
    O'Brien, PE
    GASTROENTEROLOGY, 2001, 121 (01) : 91 - 100